Open-to-Accrual Therapeutic Trials


Genitourinary Oncology

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site

Phase

CA01800f (Fraction-RCC) ClinicalTrials.gov: NCT02996110

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study of Participants with Advanced Renal Cell Carcinoma J. Parikh  Kelly Jenkins Renal Cell Carcinoma II

CX-839-008 ClinicalTrials,gov: NCT03428217

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib vs. Placebo with Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma J. Parikh Kelly Jenkins Renal Cell Carcinoma II
SGN22E-001 ClinicalTrials.gov:  NCT03219333 A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Recived Immune Checkpoint Inhibitor (CPI) Therapy J. Parikh Kelly Jenkins Urothelial Cancer II

MK3475-641 ClinicalTrials.gov:  NCT03834493

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) J. Parikh Kelly Jenkins Prostate Cancer III

MK3475-921 ClinicalTrials.gov:  NCT03834506

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE921 J. Parikh Kelly Jenkins Prostate Cancer III

MK7339-010 ClinicalTrials.gov:  NCT03834519 

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010) J. Parikh Kelly Jenkins Prostate Cancer III